Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor



Status:Archived
Conditions:Breast Cancer, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Cancer, Cancer, High Blood Pressure (Hypertension), Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:March 2010

Use our guide to learn which trials are right for you!

A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension


RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer
receiving bevacizumab may help doctors learn more about changes that occur in DNA and
identify biomarkers related to high blood pressure.

PURPOSE: This phase I trial is studying potential biomarkers for bevacizumab-induced high
blood pressure in patients with malignant solid tumors, including breast cancer, colorectal
cancer, non-small cell lung cancer, head and neck cancer, ovarian cancer, fallopian tube
cancer, or primary peritoneal carcinoma.


OBJECTIVES:

Primary

- To measure the endothelial function over time, including non-invasive assessment of
digital-pulse amplitude via Endo-pat test, serum tPA, PAI-1, VEGF, urine TXa2, and
PGI-M, in patients with solid malignancies treated with chemotherapy with or without
bevacizumab.

- To compare endothelial function changes between patients who develop hypertension (HTN)
versus patients who do not develop HTN.

Secondary

- To compare circulating soluble cytokines, proangiogenic factors, glucose tolerance, and
cardiac biomarkers over time in these patients.

- To compare endothelial progenitor cell levels pre- and post-bevacizumab in these
patients.

- To assess whether physical fitness level at baseline and at 3 months after treatment
initiation (assessed subjectively by questionnaire) correlates with relative risk of
developing NCI grade ≥ I cardiotoxicity.

OUTLINE: Patients undergo 24-hour blood pressure monitoring at baseline, before second
bevacizumab therapy, and periodically during study. Patients also undergo a digital-pulse
amplitude measurement periodically during study.

Blood samples are collected at baseline and periodically during study for circulating
soluble cytokines, proangiogenic factors, glucose tolerance, cardiac biomarkers, and
endothelial progenitor cell level studies. Patients also undergo 24-hour urine sample
collection at baseline and periodically during study for protein, creatinine, and
metabolites of prostacyclin and thromboxane.

Patients complete physical activity questionnaires at baseline and at 3 months.


We found this trial at
2
sites
Nashville, Tennessee 37212
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Franklin, TN
Click here to add this to my saved trials